The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis

摘要: The association between PIK3CA mutation and resistance to anti-HER2 therapy (AHT) is not precisely defined. This meta-analysis intended explore the clinical utility of in HER2-positive breast cancer treated with AHT. Literature search identified 19 eligible studies. There were 1720 patients advanced, 828 early 1290 neoadjuvant setting. In metastatic cancer, AHT showed no differential objective response benefit wild type (WT) mutated (MT) subgroups (odds ratio [OR] = 1.09; 95 % CI 0.60–2.00; P 0.78). favorable affected progression-free survival (PFS) irrespective mutation. was PFS difference WT MT regardless offered therapy. trastuzumab combined same chemotherapy conferred consistent relapse-free (WT: HR 0.59; 0.44–0.80; < 0.001 vs. MT: 0.42; 0.24–0.74; 0.001). setting, AHT-based produced a 72 higher pathologic complete (pCR) rate as compared that tumors (OR 1.72; 1.29–2.13; there disease-free or overall based on mutational status. this meta-analysis, did achieve according cancer; however, harboring attained pCR rate.